COCP Cocrystal Pharma (COCP) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001412486
Activist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
What the filings say about COCP
Insiders, 180 days
+$80.4K net bought
1 buyer
Activist stakes (13D), 180 days
1 filing
Largest: 29.6% of the class
Cocrystal Pharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Cocrystal Pharma, Inc. insiders bought a net $80.4K of stock across 13 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Aug 3, 2026.
- +7.4% median (+11.9% mean) 90-day return after 9 previous buys.
- The trade is 0.5% of the 1,993,551 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FROST PHILLIP MD ET AL bought about $9.8K of COCP on Aug 5, 2026; 9 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Feb 24, 2026.
- +7.4% median (+11.9% mean) 90-day return after 9 previous buys.
- The trade is 3.8% of the 1,983,551 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FROST PHILLIP MD ET AL bought about $70.6K of COCP on Aug 3, 2026, the largest insider purchase at the company since 2023; 9 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Feb 6, 2026.
- +6.8% median (+11.8% mean) 90-day return after 8 previous buys.
- The trade is 1.0% of the 1,908,551 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FROST PHILLIP MD ET AL bought about $20.0K of COCP on Feb 24, 2026; 9 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Dec 31, 2025.
- +6.2% median (+7.2% mean) 90-day return after 7 previous buys.
- The trade is 2.6% of the 1,888,551 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FROST PHILLIP MD ET AL bought about $47.5K of COCP on Feb 6, 2026; 9 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Dec 30, 2025.
- +6.8% median (+7.9% mean) 90-day return after 6 previous buys.
- The trade is 2.7% of the 1,838,551 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FROST PHILLIP MD ET AL bought about $47.5K of COCP on Dec 31, 2025, the largest insider purchase at the company since 2023; 9 funds added in the latest 13F quarter.13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$80.4K over 180 days
+$80.4K over 90 days · +$80.4K of it by a 10%+ holder
more than 75% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
-69.3% year over year
below 85% of Pharma & Biotech
Margin
-438.5% net margin
below 77% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.5% of the float short (float per yahoo 2026-10-27) · 4.9 days to cover · settled 2026-10-15
below 73% of Pharma & Biotech
The situation: each line is one rule over one dataset
OPKO HEALTH, INC. disclosed a 5%+ stake (29.6%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch COCP
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-8.5%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns COCP: institutional holders (13F)
13F holdings, latest reported quarter
358,228 sh
$376.1K
179,628 sh
$188.6K
175,379 sh
$184.1K
76,208 sh
$80.0K
73,746 sh
$77.4K
Congress trades in COCP
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
OPKO HEALTH, INC.
Activist 13D · 2026-08-07
29.6%
FROST PHILLIP MD ET AL
Activist 13D · 2026-08-07
13.9%
Frost Gamma Investments Trust
Activist 13D · 2026-08-07
13.6%
Rubin Steven D
Activist 13D · 2026-08-07
14.1%
COCP planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
COCP mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD EXTENDED MARKET INDEX FUND
$179.5K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$55.8K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$6.9K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$10.8K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$196.6K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$9.5K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
1
Phase 2
0 active
1
Multi-phase
0 active
What changed recently
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adul
2026-10-23 · Recruiting → Completed
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$1.2M
$924.8K
n/a
-75%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $80.4K bought by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
COCP financials
Revenue growth
-69.3%
XBRL, annual
Net margin
-438.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM COCP
| FY Dec 2025 | $2.0M |
| FY Dec 2024 | $2.0M |
| FY Dec 2023 | $2.0M |
| FY Dec 2022 | $2.0M |
| FY Dec 2021 | $2.0M |
| Jun 2026 | $105.0K |
| Mar 2026 | $225.0K |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM COCP
| FY Dec 2025 | -438.5% |
| FY Dec 2024 | -869.1% |
| FY Dec 2023 | -892.9% |
| FY Dec 2022 | -1,928% |
| FY Dec 2021 | -704.3% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM COCP
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$16.5M |
| FY Dec 2023 | -$14.8M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -$12.8M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$1.7M |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$3.2M |
| Sep 2024 | -$5.1M |
At each fiscal year end
Single quarter
Debt to equity
1.95x
long-term debt only, 2018-03-31 (100 months older than the period end); equity 2026-06-30
Debt to equity COCP
| FY Dec 2025 | 0.32x |
| FY Dec 2024 | 0.21x |
| FY Dec 2023 | 0.08x |
| FY Dec 2022 | 0.05x |
| FY Dec 2021 | 0.03x |
| Jun 2026 | 1.95x |
| Mar 2026 | 0.50x |
| Dec 2025 | 0.32x |
| Sep 2025 | 0.27x |
| Jun 2025 | 0.38x |
| Mar 2025 | 0.28x |
| Dec 2024 | 0.21x |
| Sep 2024 | 0.16x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.90x
TTM operating cash flow over long-term debt only, 2018-03-31 (100 months older than the period end)
Cash flow to debt COCP
| FY Dec 2025 | -4.02x |
| FY Dec 2024 | -8.08x |
| FY Dec 2023 | -7.19x |
| FY Dec 2022 | -10.51x |
| FY Dec 2021 | -6.24x |
| Jun 2026 | -3.90x |
| Mar 2026 | -3.72x |
| Dec 2025 | -4.02x |
| Sep 2025 | -4.72x |
| Jun 2025 | -6.56x |
| Mar 2025 | -7.32x |
| Dec 2024 | -8.08x |
| Sep 2024 | -8.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-311.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity COCP
| FY Dec 2025 | -111.4% |
| FY Dec 2024 | -97.5% |
| FY Dec 2023 | -54.5% |
| FY Dec 2022 | -66.3% |
| FY Dec 2021 | -21.8% |
| Jun 2026 | -311.7% |
| Mar 2026 | -154.6% |
| Dec 2025 | -111.4% |
| Sep 2025 | -94.9% |
| Jun 2025 | -110.6% |
| Mar 2025 | -106.1% |
| Dec 2024 | -97.5% |
| Sep 2024 | -86.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-151.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets COCP
| FY Dec 2025 | -76.2% |
| FY Dec 2024 | -78.3% |
| FY Dec 2023 | -49.9% |
| FY Dec 2022 | -64.6% |
| FY Dec 2021 | -21.2% |
| Jun 2026 | -151.1% |
| Mar 2026 | -97.6% |
| Dec 2025 | -76.2% |
| Sep 2025 | -72.5% |
| Jun 2025 | -83.5% |
| Mar 2025 | -85.2% |
| Dec 2024 | -78.3% |
| Sep 2024 | -76.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital COCP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-232.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed COCP
| FY Dec 2025 | -97.3% |
| FY Dec 2024 | -91.6% |
| FY Dec 2023 | -54.9% |
| FY Dec 2022 | -66.1% |
| FY Dec 2021 | -21.8% |
| Jun 2026 | -232.2% |
| Mar 2026 | -129.8% |
| Dec 2025 | -97.3% |
| Sep 2025 | -84.2% |
| Jun 2025 | -99.4% |
| Mar 2025 | -97.7% |
| Dec 2024 | -91.6% |
| Sep 2024 | -85.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing COCP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$13.7M
market value at close 2026-10-26 on 2026-08-13 shares, plus long-term debt only, 2018-03-31 (100 months older than the period end), minus cash 2025-12-31
Enterprise value COCP
| FY Dec 2025 | $8.5M |
| FY Dec 2024 | $12.7M |
| FY Dec 2023 | -$6.8M |
| FY Dec 2022 | -$19.2M |
| FY Dec 2021 | $703.6M |
| Jun 2026 | $9.5M |
| Mar 2026 | $8.9M |
| Dec 2025 | $8.5M |
| Sep 2025 | $5.0M |
| Jun 2025 | $7.3M |
| Mar 2025 | $6.6M |
| Dec 2024 | $12.7M |
| Sep 2024 | $1.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield COCP
| FY Dec 2025 | n/a |
| FY Dec 2024 | -80.3% |
| FY Dec 2023 | -84.5% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -1.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -75.0% |
| Jun 2025 | -88.3% |
| Mar 2025 | -103.3% |
| Dec 2024 | -80.3% |
| Sep 2024 | -93.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing COCP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$9.0M | -$17.9M | -$18.6M | -$38.8M |
| Net income | -$8.8M | -$17.5M | -$18.0M | -$38.8M |
| EPS (diluted) | -0.78 | -1.72 | -1.87 | -4.77 |
| Operating cash flow | -$8.2M | -$16.5M | -$14.7M | -$21.4M |
| Cash | $7.0M | $9.9M | $26.4M | $37.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
COCP Stock Sonar score 6/7 axes
Find similar shapesCompareCOCP ranks highest on risk and compliance (71st percentile) and insider conviction (65th), and lowest on profitability (12th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
COCP filings, in plain words
Are Cocrystal Pharma insiders buying or selling COCP?
In the 180 days to 2026-10-28, Cocrystal Pharma insiders were net buyers, a net $80.4K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Cocrystal Pharma insiders were net buyers of COCP, a net $80.4K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $80.4K, came from a holder of 10% or more rather than an officer or director. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 29.6% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
